FLICKR, NIAIDA variety of firms—from small biotechs to pharma giants—are working to develop Ebola vaccines and shepherd them through expedited clinical trials in cooperation with global regulatory agencies. This week, The Scientist caught up with the president and CEO of Atlanta-based GeoVax, a seven employee-strong company that hopes to have its Ebola vaccine candidate ready for human trials in 15 to 18 months.
“In the world of vaccines, we know from experience, it takes a lot of tries to get it right. It doesn’t happen overnight, and no one group is going to have the perfect vaccine,” said Robert McNally, GeoVax chief executive.
WIKIMEDIA, TWINSUK
Host genetics can influence the composition of the gut microbiome, according to an analysis of twin study data published in Cell this week. Cornell University’s Ruth Ley and her colleagues showed that the presence of several bacterial taxa can be tied to human genotypes.
“We thought perhaps there would be a few taxa here and there that might be heritable, ...
